Engineered exosomes carrying a dual miR-195/miR-188 sponge in senescent AD-MSCs
In this abstract, exosomes from Wharton's jelly mesenchymal stem cells were engineered to carry a dual miR-195/miR-188 sponge; in replicative senescent adipose-derived mesenchymal stem cells, treatment lowered both microRNAs and reduced senescence markers. [1]
Automatic summary · not editorially reviewed
The key findings
Exosomes from Wharton's jelly mesenchymal stem cells were engineered to deliver a dual miR-195/miR-188 sponge. [1]
Sponge-loaded exosomes significantly reduced intracellular levels of miR-195 and miR-188. [1]
Suppression of the two microRNAs was associated with restored telomere length and reactivation of SOX2 and OCT4. [1]
The source at a glance
- Study type / format
- Abstract of a laboratory cell study
- Population / context
- Replicative senescent adipose-derived mesenchymal stem cells (AD-MSCs) in cell assays.
- Summary based on
- Study abstract
- Original publication
- October 8, 2026
Senescent fat-derived stem cells and a dual microRNA sponge
The abstract states that cellular senescence impairs the regenerative potential of adipose-derived mesenchymal stem cells (AD-MSCs). It names miR-195 and miR-188 as regulators of aging-associated pathways and describes them as targets for modulating senescence. Exosomes from Wharton's jelly mesenchymal stem cells were engineered to deliver a dual miR-195/miR-188 sponge.
Supporting source [1]
Lower microRNA levels and reduced senescence markers in cells
According to the abstract, sponge-loaded exosomes significantly reduced intracellular levels of miR-195 and miR-188. Treatment significantly reduced senescence markers including p16, p53, NF-κB, IL-6 and RB, and decreased reactive oxygen species and β-galactosidase activity. Suppression of the two microRNAs was associated with restored telomere length and reactivation of SOX2 and OCT4, suggesting modulation of telomere maintenance and p53-RB signaling. Clonogenic capacity and viability were markedly enhanced.
Supporting source [1]
Cell-level findings only; full text not reviewed
These results come from functional assays in replicative senescent AD-MSCs, as reported in the abstract. The abstract describes the approach as a promising cell-free nucleic acid therapeutic platform for regenerative medicine; this is a proposed direction, not a demonstrated treatment in humans. The abstract does not report sample sizes, follow-up or human outcomes. Only the abstract was reviewed; the full text was not reviewed.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. Findings are from cell assays in replicative senescent AD-MSCs; no sample sizes, follow-up or human outcomes are reported. Associations are not causes, and the therapeutic platform is proposed, not established.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Elmi F, Azizsoltani A, Taghizadeh M, Eslaminejad MB, Alizadeh E. · europepmc.org · October 8, 2026